전립선암 진단 시장 : 제품 유형, 검사 유형, 용도, 최종 사용자별 - 세계 시장 예측(2026-2032년)

The Prostate Cancer Diagnostics Market is projected to grow by USD 13.52 billion at a CAGR of 8.92% by 2032.

Prostate cancer diagnostics are moving from episodic PSA-driven testing toward risk-adapted pathways that combine prostate-specific antigen testing, digital rectal examination, multiparametric MRI, targeted biopsy, histopathology, and molecular biomarkers. This shift is clinically important because prostate cancer remains one of the most commonly diagnosed cancers in men worldwide, with GLOBOCAN 2022 estimating approximately 1.47 million new cases and nearly 397,000 deaths globally.

Demand for prostate cancer diagnostics is being shaped by aging male populations, higher awareness of early detection, expanded access to urology services, and the need to reduce unnecessary biopsies while identifying clinically significant disease. For industry visibility, the core themes include prostate cancer diagnostics, PSA testing, prostate MRI, prostate biopsy, liquid biopsy, genomic testing, AI pathology, and precision oncology.

Transformative Shifts in the Diagnostic Landscape

The diagnostic landscape is being transformed by the use of multiparametric MRI before biopsy, growing reliance on MRI-ultrasound fusion biopsy, and broader clinical acceptance of reflex biomarker tests that improve specificity beyond PSA alone. These tools help clinicians distinguish indolent tumors from clinically significant prostate cancer, supporting more appropriate use of active surveillance, surgery, radiotherapy, and systemic therapy.

Another major shift is the integration of molecular diagnostics and genomic classifiers into treatment planning. Tests that evaluate tumor biology, inherited risk, or actionable mutations are becoming more relevant as prostate cancer care aligns with precision medicine, especially for patients with high-risk, recurrent, or metastatic disease. Clinical guidelines increasingly support risk-based decision-making that incorporates PSA density, MRI findings, family history, pathology grade, and genomic information.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is creating cumulative value across imaging, pathology, workflow triage, and decision support. In prostate MRI, AI tools are being developed to assist lesion detection, PI-RADS assessment, segmentation, and reporting consistency. In digital pathology, AI can support Gleason grading, tumor quantification, quality control, and workload prioritization, particularly in high-volume laboratories.

The impact is strongest when AI is positioned as an assistive layer rather than a replacement for clinical judgment. Hospitals, imaging centers, and diagnostic laboratories are evaluating AI based on validation quality, interoperability, cybersecurity, regulatory clearance, and evidence that it improves sensitivity, specificity, turnaround time, or reader agreement in real-world practice. As datasets expand, AI-enabled prostate cancer diagnostics are expected to support more standardized interpretation across radiology and pathology environments.

Key Regional Insights Across Global Markets

North America remains a leading region for prostate cancer diagnostics because of high screening awareness, advanced imaging capacity, reimbursement pathways, and strong adoption of genomic tests in the United States and Canada. Europe benefits from structured cancer programs, guideline-driven use of multiparametric MRI, and national health systems that increasingly prioritize early diagnosis, although access and reimbursement vary across countries. Across the European region, organized referral pathways and strong radiology-pathology collaboration are supporting broader use of MRI-led biopsy strategies.

Asia-Pacific is expanding as China, India, Japan, South Korea, and Australia invest in oncology infrastructure, MRI capacity, pathology modernization, and private diagnostic networks. Latin America, led by Brazil and Mexico, shows rising demand for PSA testing, prostate biopsy, and imaging services but faces uneven access to advanced MRI and molecular testing. The Middle East, especially Gulf health systems, is investing in tertiary oncology centers, digital health infrastructure, and specialist training, while Africa remains constrained by specialist shortages, lower screening penetration, and limited access to MRI, biopsy, and pathology services outside major urban centers.

Key Group Insights Across Economic and Policy Blocs

Within ASEAN, demand is supported by expanding private hospitals, medical tourism hubs, and government cancer-control initiatives, though access to advanced prostate MRI, fusion biopsy, and genomic testing remains concentrated in larger cities. The GCC is building high-acuity oncology capacity through public investment, national cancer strategies, digital health programs, and procurement of advanced diagnostic platforms, creating a favorable environment for premium prostate cancer diagnostics.

The European Union is influential because of harmonized regulatory standards, strong clinical guideline adoption, and research funding for cancer diagnostics, including imaging, biomarkers, and digital pathology. BRICS economies combine large patient populations with rising healthcare investment, creating long-term opportunities for scalable PSA testing, imaging, pathology, and molecular diagnostics. G7 countries lead in adoption of advanced diagnostic workflows and precision oncology infrastructure, while NATO member markets overlap with many advanced Western health systems where digital pathology, AI validation, data protection, and cybersecurity are increasingly important procurement priorities.

Key Country Insights in Prostate Cancer Diagnostics

The United States is a major innovation and commercialization hub for prostate cancer diagnostics, supported by advanced urology networks, broad imaging access, molecular testing capabilities, and extensive clinical trial activity. Canada emphasizes guideline-based care and equitable access, while Mexico and Brazil are expanding private diagnostics and oncology capacity despite access gaps between metropolitan and underserved regions. The United Kingdom, Germany, France, Italy, and Spain are advancing multiparametric MRI-led diagnostic pathways, with Germany and France showing strong diagnostic technology adoption and the United Kingdom emphasizing earlier cancer diagnosis through national health programs.

Russia maintains demand through large urban oncology centers, although technology access can vary by region. China is scaling cancer diagnostics through hospital expansion, domestic medtech development, and rising awareness of men's health. India has substantial long-term growth potential due to demographics, expanding private-sector diagnostics, and increasing oncology investment, but affordability and specialist availability remain central. Japan, South Korea, and Australia are mature Asia-Pacific markets with strong imaging, pathology, and precision oncology capabilities, supporting adoption of prostate MRI, biomarker testing, targeted biopsy, and AI-enabled diagnostic workflows.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically validated solutions that reduce unnecessary biopsy, improve detection of clinically significant prostate cancer, and integrate smoothly into urology, radiology, and pathology workflows. Partnerships with academic medical centers, cancer hospitals, reference laboratories, and public health stakeholders can accelerate evidence generation and improve physician confidence.

Commercial teams should build region-specific market access strategies, including reimbursement dossiers, health-economic evidence, regulatory planning, and education for urologists, radiologists, pathologists, oncologists, and primary care physicians. Organizations should also invest in interoperability, cybersecurity, AI governance, and post-deployment performance monitoring to meet procurement requirements in hospitals, laboratories, and integrated delivery networks.

Research Methodology

This executive summary is grounded in secondary research from recognized public-health sources, cancer epidemiology databases, clinical guidelines, regulatory information, peer-reviewed literature, and diagnostic industry activity. Key reference domains include global cancer incidence reporting, national screening and diagnostic recommendations, imaging and pathology standards, biomarker evidence, and published studies on AI-assisted prostate cancer diagnostics.

The analysis applies triangulation across epidemiology, clinical adoption, reimbursement environment, technology maturity, regulatory readiness, and regional healthcare infrastructure. Insights were synthesized to identify durable market drivers, restraints, adoption patterns, and commercialization priorities without relying on unverified claims, market sizing, market share, or speculative forecasting.

Conclusion

The prostate cancer diagnostics landscape is entering a more precise, data-driven phase in which PSA testing remains foundational but is increasingly complemented by multiparametric MRI, targeted biopsy, biomarkers, genomic profiling, liquid biopsy research, digital pathology, and AI-enabled workflow support. The strongest adoption momentum will come from technologies that demonstrate clinical utility, improve risk stratification, and fit into real-world care pathways.

For industry participants, success will depend on evidence quality, reimbursement alignment, scalable deployment, regulatory compliance, and trust among clinicians. Organizations that combine robust science with accessible implementation models will be best positioned to address demand across mature and emerging healthcare systems while improving the early detection and management of clinically significant prostate cancer.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Prostate Cancer Diagnostics Market, by Product Type

• 7.1. Biomarkers & Kits
  • 7.1.1. Genetic Testing Kits
  • 7.1.2. Molecular Diagnostic Kits
  • 7.1.3. Psa Tests
• 7.2. Biopsy Needles
• 7.3. Imaging Systems
  • 7.3.1. Ct Systems
  • 7.3.2. Mri Systems
  • 7.3.3. Pet Systems
  • 7.3.4. Ultrasound Systems

8. Prostate Cancer Diagnostics Market, by Test Type

• 8.1. Biopsy
• 8.2. Imaging Tests
  • 8.2.1. Ct Tests
  • 8.2.2. Mri Tests
  • 8.2.3. Pet Tests
  • 8.2.4. Ultrasound Tests
• 8.3. Molecular Tests
  • 8.3.1. Ngs Tests
  • 8.3.2. Pcr Tests
• 8.4. Psa Test

9. Prostate Cancer Diagnostics Market, by Application

• 9.1. Genetic Testing
• 9.2. Initial Diagnosis
• 9.3. Monitoring & Follow-Up

10. Prostate Cancer Diagnostics Market, by End User

• 10.1. Ambulatory Surgical Centers
• 10.2. Diagnostic Centers
• 10.3. Hospitals & Clinics
• 10.4. Research Laboratories

11. Prostate Cancer Diagnostics Market, by Region

• 11.1. Asia-Pacific
• 11.2. North America
• 11.3. Latin America
• 11.4. Europe
• 11.5. Middle East
• 11.6. Africa

12. Prostate Cancer Diagnostics Market, by Group

• 12.1. ASEAN
• 12.2. GCC
• 12.3. European Union
• 12.4. BRICS
• 12.5. G7
• 12.6. NATO

13. Prostate Cancer Diagnostics Market, by Country

• 13.1. United States
• 13.2. Canada
• 13.3. Mexico
• 13.4. Brazil
• 13.5. United Kingdom
• 13.6. Germany
• 13.7. France
• 13.8. Russia
• 13.9. Italy
• 13.10. Spain
• 13.11. China
• 13.12. India
• 13.13. Japan
• 13.14. Australia
• 13.15. South Korea

14. Competitive Landscape

• 14.1. Market Concentration Analysis, 2025
  • 14.1.1. Concentration Ratio (CR)
  • 14.1.2. Herfindahl Hirschman Index (HHI)
• 14.2. Recent Developments & Impact Analysis, 2025
• 14.3. Product Portfolio Analysis, 2025
• 14.4. Benchmarking Analysis, 2025

15. Company Profiles

• 15.1. Abbott Laboratories
• 15.2. Agilent Technologies, Inc.
• 15.3. Beckman Coulter, Inc.
• 15.4. Becton, Dickinson and Company
• 15.5. bioMerieux S.A.
• 15.6. DiaSorin S.p.A.
• 15.7. F. Hoffmann-La Roche Ltd
• 15.8. Fujifilm Holdings Corporation
• 15.9. Fujirebio Holdings, Inc.
• 15.10. GE HealthCare Technologies Inc.
• 15.11. Genomic Health, Inc.
• 15.12. Guardant Health, Inc.
• 15.13. Illumina, Inc.
• 15.14. Koninklijke Philips N.V.
• 15.15. Laboratory Corporation of America Holdings
• 15.16. MDxHealth SA
• 15.17. Myriad Genetics, Inc.
• 15.18. OPKO Health, Inc.
• 15.19. Proteomedix AG
• 15.20. QIAGEN N.V.
• 15.21. Quest Diagnostics Incorporated
• 15.22. Siemens Healthineers AG
• 15.23. Sysmex Corporation
• 15.24. Thermo Fisher Scientific Inc.
• 15.25. Veracyte, Inc.